MR angiography with blood pool contrast agents

Contrast-enhanced magnetic resonance angiography (CE-MRA) with standard extracellular contrast material is well established for vascular imaging. Recently, the first blood pool contrast agent (BPA) has become clinically available. This paper reviews characteristics and classification of BPA as well as first clinical experience in various vascular territories. BPAs comprise gadolinium-based compounds, synthetic compounds, and ultrasmall superparamagnetic iron-oxide (USPIO) particles. Such BPAs are retained in blood with a prolonged time-window of enhancement as compared to extracellular gadolinium chelates. Promising results from USPIO at first-pass and steady-state angiography have been published, but no USPIO is approved yet. Gadofosveset is the first clinically approved BPA. After bolus injection, gadofosveset binds noncovalently to serum-albumine, thus enhancing relaxivity. First published results from carotid, coronary, renal, and peripheral angiography are encouraging; particularly helpful is prolonged enhancement during steady state. More BPAs have been clinically evaluated, but no approval has been granted. Bolus-injectable BPAs allow for first-pass CE-MRA similar to standard extracellular contrast media, but with higher relaxivity, allowing lower doses and reduced injection rates. An additional feature of BPA is the steady-state phase with a broad time window enabling high-resolution angiography or double-gated angiography of coronary arteries to compensate for the complex motion pattern.     

Contrast-enhanced 3D-TOF MRA of peripheral vessels: Intravascular versus extracellular MR contrast media

MR contrast media have been used to improve MR angiography (MRA). Their effect has been particularly beneficial for extracranial MRA. This study evaluated the efficacy of a new formulation of ultrasmall super-paramagnetic iron oxide particles (USPIO) on three-dimensional (3D) time of flight (TOF) MRA in the pelvis and lower limb circulation. Each of six dogs received 3 mg/kg of USPIO and .2 mmol/kg of gadolinium-dieth-ylenetriamine pentaacetic acid (Gd-DTPA) bis-meth-ylamide (BMA) by intravenous infusion on separate examinations. Precontrast and postcontrast 3D-TOF MRA images of the lower extremities were acquired over the course of 45 minutes postinjection. Signal intensity (SI) was measured on axial views along the external iliac, femoral, and popliteal arteries. USPIO provided clear demarcation of the major primary, secondary, and tertiary vessels and the improved contrast-to-noise ratio (CNR) was maintained for 45 minutes. Gd-DTPA-BMA provided less signal enhancement than USPIO. The increase in CNR with this agent had significantly declined by 15 minutes after injection. The major vessels could no longer be visualized at 30 and 45 minutes after injection of Gd-DTPA-BMA. This study demonstrates the efficacy of USPIO as a contrast medium for 3D-TOF MRA. It was concluded that USPIO provided effective and persistent enhancement of the peripheral vessels.     

Dynamic magnetic resonance angiography of the arteries of the hand. A comparison between an extracellular and an intravascular contrast agent

The purpose of this study was to compare the image quality of the intravascular contrast agent gadofosveset with the extracellular contrast agent gadoterate meglumine in time-resolved three-dimensional magnetic resonance (MR) angiography of the human arteries of the hand. The value of cuff compression technique for suppression of venous enhancement for both contrast agents was also investigated. Three-dimensional MR angiograms of both hands of 11 healthy volunteers were acquired for each contrast agent at 1.5-T, while subsystolic cuff compression was applied at one side. Quantitative and qualitative evaluation were performed and analyzed with Student’s t-test. Visualization of vessels was superior in the images acquired with gadofosveset, especially in the late phases. Quantitative and qualitative evaluation showed significantly higher values for gadofosveset. The cuff compression at the lower arm proved to be an effective method to enhance arterial vessels. In conclusion the blood pool agent gadofosveset is superior for the dynamic imaging of the vessels of the hand when compared with the extracellular contrast agent gadoterate meglumine. To fully utilize the advantages of intravascular contrast agents, venous overlay has to be delayed or reduced, which can be achieved effectively by subsystolic lower arm cuff compression.     

USPIO-enhanced magnetic resonance imaging of the knee in asymptomatic volunteers

The aim of this study was to compare signal characteristics of the synovium in knees of asymptomatic volunteers before and after intravenous administration of ultrasmall superparamagnetic iron oxide particles (USPIO). Ten knees of 10 asymptomatic volunteers were examined before and 36 h after intravenous administration of USPIO on a 1.5-T MR system using T1-weighted spin-echo, T2-weighted fast spin-echo, T2*-weighted gradient-echo (GRE), and short inversion time inversion-recovery sequences. In addition, synovial perfusion was measured using Gd-enhanced GRE imaging during the first imaging session. Images were analyzed qualitatively for any visual changes before and after USPIO administration. Signal-to-noise ratios (SNR) of the synovium were determined on unenhanced and USPIO-enhanced sequences. All MR images were reviewed for presence of any degenerative changes. Qualitative image analysis revealed no visually detectable changes of any knee joint before and after USPIO administration. The SNR values of the synovium on T1w, T2w, and T2*w images before and after USPIO administration showed no significant difference (T1, P = 0.86; T2, P = 0.95; T2*, P = 0.86). None of the volunteers showed any relevant degenerative changes of the knee and synovial perfusion was within normal limits. In knees of asymptomatic volunteers without any relevant degenerative changes and normal synovial perfusion neither visual changes nor changes of SNR values of the synovium can be depicted after USPIO administration. This means that USPIO-enhanced MRI may be used for assessment of knee disorders with increased macrophage activity.     

Coronary magnetic resonance angiography: experimental evaluation of the new rapid clearance blood pool contrast medium P792.

The signal-enhancing characteristics of a new monodisperse monogadolinated macromolecular MR contrast medium (P792) were evaluated for magnetic resonance angiography (MRA) of the coronary arteries. A total of 15 cardiac examinations were performed in pigs at 1.5 T using a 3D gradient-echo sequence. Images were acquired during breath-hold before and up to 35 min after IV injection of Gd-DTPA (0.3 mmol Gd/kg), Gd-BOPTA (0.2 mmol Gd/kg), and P792 (13 micromol Gd/kg). An increase in the signal-to-noise ratio (SNR) of 97% +/- 17%, 108% +/- 37%, and 109% +/- 31% in coronary arteries and of 82% +/- 19%, 82% +/- 24%, and 28% +/- 18% in myocardium, respectively, was measured during the first postcontrast acquisition. The blood-to-myocardium signal-difference-to-noise ratio (SDNR) was significantly higher for P792 than for the other Gd compounds (P <.05) for up to 15 min after injection. Qualitative assessment showed that visualization of the coronary arteries and their branches was significantly better for P792 compared to the low-molecular Gd compounds (P <.05). The blood pool contrast medium P792 is well suited for MRA of the coronary arteries.     

Multislice breath-hold spiral magnetic resonance coronary angiography in patients with coronary artery disease: effect of intravascular contrast medium

PURPOSE: First, to apply a breath-hold multislice 2D spiral magnetic resonance (MR) approach in patients acquiring within 16 heartbeats (acquisition window, 116 msec) a 10-mm-thick stack of four slices (resolution, 1.3 x 1.3 mm(2)); and second, to evaluate the effect of an intravascular Fe-based contrast medium (CM) on a signal-to-noise ratio (SNR) and a contrast-to-noise ratio (CNR). MATERIALS AND METHODS: In each patient one or two coronary arteries were imaged prior to and following cumulative doses of 0.25, 0.5, and 0.75 mg of Fe/kg of body weight (bw) of an intravascular CM (CLARISCAN trade mark, Nycomed-Amersham, Princeton, NJ, USA) containing ultrasmall superparamagnetic iron oxide (USPIO) particles. RESULTS: On precontrast maximum intensity projection (MIP) images generated from the stack of slices, 10 and 11 stenoses of 12 stenoses confirmed by coronary angiography were detected by readers 1 and 2, respectively. SNR and CNR in the coronary arteries peaked at 0.50 mg of Fe/kg of bw, yielding a slight increase of 15.5% and 18.4%, respectively (P < 0.05 vs. precontrast), which did not improve detection of coronary artery stenoses. CONCLUSION: The presented multislice spiral approach allows display of coronary anatomy in MIP formats for convenient display of coronary stenoses. The pulse sequence did not benefit from an intravascular USPIO-based CM, since little improvement in SNR and CNR was achieved.     

Value of a blood pool contrast agent in MR venography of the lower extremities and pelvis: preliminary results in 12 patients.

The purpose of this study was to determine the value of a blood-pool contrast media (NC100150, Nycomed Imaging (now Amersham Health) Oslo, Norway) for evaluation of venous thrombosis of the deep veins of the pelvis and lower extremities. Twelve patients were prospectively evaluated with conventional X-ray venography (XRV) and MR venography (MRV) after injection of NC100150 (2 ml/kg body weight). The source images and 3D maximum intensity projection (MIP) were viewed on an independent workstation. Diagnosis was made in consensus from two radiologists. Diagnostic image quality was achieved in 87 veins with XRV and MRV. As determined by XRV, thrombus was present in 30 out of 87 veins (34.5%). There was agreement concerning absence or presence of thrombi in 83 out of 87 veins (95.4%; kappa = 0.9 +/- 0.05). Compared to XRV, overall sensitivity and specificity of blood-pool MRV were 93.3% and 96.5%, respectively. Two venous thromboses of the popliteal and posterior tibial vein were diagnosed in MRV, but not in XRV. Conversely, two venous thromboses below the knee had been missed by MRV. NC100150 allows prolonged and improved visualization of the peripheral vasculature and may overcome some limitations of gadolinium contrast media. A more complete examination of the proximal venous tree may be possible than with conventional XRV. Arterial and venous enhancement and motion artifacts can limit image interpretation.     

Contrast-enhanced magnetic resonance angiography of the lower extremities: standard-dose vs. high-dose gadodiamide injection

PURPOSE: To compare the efficacy and safety of two different doses (0.1 and 0.3 mmol/kg of body weight [BW]) of gadodiamide for contrast-enhanced magnetic resonance angiography (ce-MRA) of the lower extremities with intraarterial digital subtraction angiography (IA-DSA). MATERIALS AND METHODS: A total of 30 patients with peripheral arterial occlusive disease underwent IA-DSA and ce-MRA from the aortic bifurcation down to the ankle. Patients were randomized to receive a total dose of 0.1 or 0.3 mmol/kg of BW gadodiamide (Omniscan, Amersham Buchler), administered intravenously as a series of three automatic bolus injections. Ce-MRA was performed with a 1.5-T system using a body phased-array coil, centered stepwise over the calf, thigh, and pelvic region. A fast T1-weighted, three-dimensional gradient-echo sequence was obtained before and after injection of the allocated dose. IA-DSA was performed using the Seldinger technique and a femoral approach. The vessels under investigation were divided into 31 segments, and ce-MRA and IA-DSA image sets were evaluated in a double-blind fashion for the presence of stenosis, presence of collateral vessels, vessel delineation, and overall image quality. Both dose groups were compared with regard to contrast index (CI) and signal- and contrast-to-noise ratios (SNR, CNR). The occurrence of adverse events or side effects was also documented. Sensitivity, specificity, and accuracy were calculated in relation to the results of stenosis grading. RESULTS: A total of 26 patients were entered in the efficacy evaluation, while all 30 patients were included in the safety assessment. The sensitivity, specificity, and accuracy for the 0.1 and 0.3 mmol/kg dose groups were 78.8%/93.0%/88.9% vs. 60.2.%/91.5%/83.2%, respectively. The detection of collaterals was similar to IA-DSA for the 0.3 mmol/kg dose group (30.2% vs. 27.4%), but was lower in the 0.1 mmol/kg dose group (27.3% vs. 12.3%). The high-dose gadodiamide injection proved to be superior to the 0.1 mmol/kg dose group with regard to vessel delineation and overall image quality (P = 0.007 and P = 0.002, respectively). The difference between the two dose groups regarding CI, SNR, and CNR was significant (P = 0.0001), in favor of the 0.3 mmol/kg dose group. No adverse events were observed in any of the patients. CONCLUSION: Ce-MRA with gadodiamide is safe and efficacious. Comparison of two different doses with IA-DSA as the standard of reference showed that the 0.3 mmol/kg dose is superior to the standard 0.1 mmol/kg dose with respect to contrast enhancement, vessel delineation, image quality, and detection of collaterals. However, the 0.1 mmol/kg dose was superior to the high dose in the grading of stenosis.     

High spatial resolution magnetic resonance imaging of experimental cerebral venous thrombosis with a blood pool contrast agent

Purpose

The purpose of this study was to investigate the feasibility of clot visualization in small sinus and cortical veins with contrast enhanced MRA in a cerebral venous thrombosis animal model using a blood pool contrast agent, Gadofosveset, and high spatial resolution imaging.

Material and methods

For induction of cerebral venous thrombosis a recently developed combined interventional and microsurgical model was used. Cerebral sinus and cortical vein thrombosis was induced in six pigs. Two further pigs died during the procedure. Standard structural, time-of-flight- and phase contrast-angiograms were followed by fast time resolved high resolution 3D MRA (4D MRA) and subsequent high spatial resolution 3D MRA in the equilibrium phase with and without addition of parallel imaging. Visualization of the clots using the different sequences was subjectively compared and contrast-to-noise ratio (CNR) was assessed.

Results

In the remaining six animals the procedure and MR-imaging protocol including administration of Gadofosveset was successfully completed. The 3D high resolution MRA in the equilibrium phase without the addition of parallel imaging was superior to all the other applied MR measurement techniques in terms of visualization of the clots. Only applying this sequence bridging vein thromboses were also seen as a small filling defect with a high CNR of >18.

Conclusion

Only the non-accelerated high spatial resolution 3D MRA in the equilibrium in conjunction with the blood pool agent Gadofosveset allows for high-contrast visualization of very small clots in the cerebral sinus and cortical veins.

Statement clinical impact

Detection of cortical vein thrombosis is of high clinical impact. Conventional MRI sequences often fail to visualize the clot. We could demonstrate that, in contrast to conventional sequences, with high spatial resolution 3D MRA in the equilibrium in conjunction with the blood pool agent Gadofosveset very small clots in the cerebral sinus and cortical veins could be successfully visualized. We think that with the presented approach cortical vein thrombosis might also be sufficiently visualized in patients.     

SENSE技术在磁共振腹部动态增强血管成像中的应用

目的：探讨磁共振敏感编码技术在腹部动态增强血管成像(DcE—MRA)中的应用优势。方法：将疑有腹部血管疾病的40例患者分为二组，实验组20例使用SENSE技术扫描；另外20例为对照组，直接行DCE—MRA扫描。结果：对照组20例中，13例因患者呼吸配合好，图像清晰，其中5例显示了动、静脉不同时相，8例由于扫描时间长，得到动、静脉均显影的图像。其余7例因屏气配合不好，图像出现伪影，为诊断带来了困难。实验组20例患者由于扫描时间明显缩短，均获得了清晰且不同时相的图像。结论：sENsE技术的使用大大地缩短了扫描时间，使腹部DCE—MRA可不受呼吸影响，并能获得不同时相血管强化图像，明显改善了DcE—MRA影像的质量，提高了诊断准确性。     

Optimization of a blood pool contrast agent injection protocol for MR angiography

PURPOSE: To design an ideal first-pass profile for MR angiography (MRA) by optimizing a multiphasic injection protocol based on two experimental animal models. MATERIALS AND METHODS: An equivalent contrast-enhanced (CE) MRA injection protocol was developed with controlled injection modalities (injection rate, volume, and dose) in rabbits and pigs. P792, a blood pool contrast agent, was injected in 17 male New Zealand rabbits and five farm pigs with variable injection schemes (mono- and multiphasic). From the gadolinium (Gd) blood concentration data, a simulation of an MR acquisition was performed to evaluate the impact of such an injection protocol on MR arterial signal and to select the best injection protocol. RESULTS: An empirical relationship between the arterial peak concentration and the injection parameters was found in the rabbits and pigs, allowing precise prediction of the first-pass profile. Of the four injection scheme strategies tested (standard bolus and bi-, tri-, and multiphasic injection protocols), the multiphasic "ramp" injection protocol provided the most optimal contrast agent pharmacokinetics with a durable plateau of concentration. CONCLUSION: Ramp injection protocol provides an optimized first-pass profile for CE-MRA.     

High‐resolution magnetic resonance angiography in the mouse using a nanoparticle blood‐pool contrast agent

High‐resolution magnetic resonance angiography is already a useful tool for studying mouse models of human disease. Magnetic resonance angiography in the mouse is typically performed using time‐of‐flight contrast. In this work, a new long‐circulating blood‐pool contrast agent—a liposomal nanoparticle with surface‐conjugated gadolinium (SC‐Gd liposomes)—was evaluated for use in mouse neurovascular magnetic resonance angiography. A total of 12 mice were imaged. Scan parameters were optimized for both time‐of‐flight and SC‐Gd contrast. Compared to time‐of‐flight contrast, SC‐Gd liposomes (0.08 mmol/kg) enabled improved small‐vessel contrast‐to‐noise ratio, larger field of view, shorter scan time, and imaging of venous structures. For a limited field of view, time‐of‐flight and SC‐Gd were not significantly different; however, SC‐Gd provided better contrast‐to‐noise ratio when the field of view encompassed the whole brain (P < 0.001) or the whole neurovascular axis (P < 0.001). SC‐Gd allowed acquisition of high‐resolution magnetic resonance angiography (52 × 52 × 100 micrometer³ or 0.27 nL), with 123% higher (P < 0.001) contrast‐to‐noise ratio in comparable scan time (～45 min). Alternatively, SC‐Gd liposomes could be used to acquire high‐resolution magnetic resonance angiography (0.27 nL) with 32% higher contrast‐to‐noise ratio (P < 0.001) in 75% shorter scan time (12 min). Magn Reson Med, 2009. © 2009 Wiley‐Liss, Inc.     

Macromolecular contrast medium (feruglose) versus small molecular contrast medium (gadopentetate) enhanced magnetic resonance imaging: differentiation of benign and malignant breast lesions

RATIONALE AND OBJECTIVES: To compare the diagnostic performance of the blood pool agent feruglose and the standard extracellular contrast agent gadopentetate in their abilities to differentiate benign and malignant breast tumors. PATIENTS AND METHODS: Fourteen women, aged 35-77 years (mean, 55 years), with 19 breast lesions underwent dynamic fast field echo 14/1/30 degrees (TR/TE/alpha) magnetic resonance imaging of the breast after bolus injection of feruglose (Clariscan; Amersham Health, Amersham, UK: dose, 2 mg Fe/kg) and an additional, comparative gadopentetate (dose, 0.2 mmol gadolinium/kg)-enhanced fast field echo 10/4/30 degrees (TR/TE/alpha) magnetic resonance study within 1-11 days (mean, 4.8 days) before or after the feruglose study. All breast tumors were surgically excised within 1-6 days (mean, 2.5 days) after completion of the magnetic resonance studies. Data were analyzed by measuring quantitative enhancement data and qualitatively by categorizations of the shape of the tumor enhancement curves. Group differences between quantitative data of the two contrast agents and between benign and malignant tumors were evaluated using a two-tailed paired-sample t test. Differences in curve type distribution between benign and malignant tumors were tested with the chi2 test. RESULTS: Histopathology showed a spectrum of 10 benign and nine malignant breast lesions: five mastopathies, two fibroadenomas, two chronic inflammations, and one papillomatosis, as well as five invasive ductal carcinomas and four invasive lobular carcinomas. Substantial differences were observed between feruglose- and gadopentetate-enhanced images: the mean tumor deltaSI(%) peak enhancement and wash-in rate were significantly higher for gadopentetate- as compared with feruglose-enhanced images (P < .05). Using either contrast agent, morphologic enhancement characteristics showed a considerable overlap between benign and malignant breast lesions. However, the kinetic enhancement profiles of benign and malignant lesions were significantly different based on feruglose-enhanced data (chi2 = 9.017; P = .0027) but not gadopentetate-enhanced data (chi2 = 2.239; P = .3264). CONCLUSION: Compared with gadopentetate, the new blood pool agent feruglose provided an improved characterization of the evaluated breast lesions; however, at the cost of weaker overall tumor enhancement.     

First-pass contrast-enhanced magnetic resonance angiography in humans using ferumoxytol, a novel ultrasmall superparamagnetic iron oxide (USPIO)-based blood pool agent

PURPOSE: To evaluate the feasibility of first-pass contrast-enhanced magnetic resonance angiography (MRA) using ferumoxytol in humans. MATERIALS AND METHODS: First-pass and equilibrium phase MRA were performed using ferumoxytol in one healthy volunteer and 11 patients with a fast three-dimensional spoiled gradient recalled (SPGR) pulse sequence. The examined vessels included carotid arteries, thoracic aorta, abdominal aorta, and peripheral arteries. A dose of either 71.6 micromol Fe/kg (n = 9), or 35.8 micromol Fe/kg (n = 3) was used. Based on a phantom study, the agent with initial concentration of 537.2 micromol Fe/mL was diluted by either four-fold (134.3 micromol Fe/mL) or eight-fold (67.1 micromol Fe/mL) for first-pass MRA. RESULTS: All subjects completed their studies without adverse events. First-pass MRA showed selective arterial enhancement, with both arterial and venous enhancement on delayed acquisitions. Selective venous enhancement could be obtained by subtraction of arterial phase images from equilibrium phase images. The findings in ferumoxytol MRA were consistent with the results of original vascular tests. CONCLUSION: Our preliminary experience supports the feasibility of first-pass MRA with ferumoxytol. Satisfactory arterial enhancement during first-pass imaging is obtained with injection of diluted contrast agent. With ferumoxytol, arteries and veins can be selectively depicted in a single exam.     

Black blood magnetic resonance angiography with Dy-DTPA polymer: Effect on arterial intraluminal signal intensity,lumen diameter,and wall thickness

Four rabbits in which atherosclerotic disease was induced by diet and balloon angioplasty underwent conventional angiography and MR angiography (MRA) using a black blood pulse sequence before and 10 minutes after the iv injection of a macromolecular contrast agent, NC 100283 (1.0 mmol/kg), a dysprosium diethylenetriaminepentaacetic acid hexamethylenediamine copolymer (Dy-DTPA polymer). Intraluminal signal intensity, apparent wall thickness, and lumen size measurements of the aorta and proximal common iliac arteries on precontract MRA images were compared with postcontrast images. Aortic lumen diameter measurements on the precontrast and postcontrast MRA studies were compared with lumen diameters from conventional angiograms. Intraluminal signal intensity decreased on postcontrast MRA images compared with precontrast images, with an average loss of signal equal to 29% (P < .05). Apparent wall thickness decreased by 24% (P < .05). Lumen diameter and area were generally larger (average of 15% and 33%, respectively) on postcontrast MRA images than on precontrast images. Aortic lumen diameter measurements from postcontrast MRA agreed closely (95% confidence interval of the mean difference was ?.2 to .3 mm), and precontrast MRA images tended to underestimate aortic lumen diameter (95% confidence interval of the mean difference was .3 to .8 mm) compared with conventional angiography. Postcontrast MRA with NC 100283, a macromolecular Dy-DTPA contrast agent, provides more accurate assessment of aortic lumen diameter than precontrast MRA, using conventional angiography as the standard reference.     

The importance of adjusting for differences in proximal and distal contrast bolus arrival times in contrast-enhanced iliac artery magnetic resonance angiography

We tested the hypothesis that differences in proximal and distal contrast bolus arrival times may result in insufficient vascular signal in the distal part of the aortoiliofemoral territory with routinely used timing techniques. The difference in arrival time of the contrast medium bolus between the aorta and the common femoral arteries was measured in 14 patients undergoing magnetic resonance angiography of the aortoiliac arteries. A dual-station test bolus technique adjusting for this difference was evaluated. The variation coefficient of the signal intensity in six defined locations and signal intensities (SI) normalised to fat were calculated. Comparisons were made with findings in 13 patients examined with a fluoroscopically triggered timing technique (BolusTrak, Philips Medical Systems, Best, The Netherlands). The difference in bolus arrival time between proximal and distal vessels was 0–7 s. In 3 of 14 patients it was 5.6–7 s. There was a tendency towards a lower mean variation coefficient in the dual-station group (p=0.10). With both techniques, significantly lower SIs were measured in the femoral arteries compared with SIs in the superior part of the abdominal aorta. In two cases in the BolusTrak group, a distal vessel could not be delineated but was shown to be patent on a delayed scan. Differences in contrast medium arrival time along the vessel may be large enough to preclude visualisation of distal vessels unless there is compensation. A dual-station test bolus technique taking this into account was found to be feasible. Electronic Publication     

Magnetic resonance VIBE venography using the blood pool contrast agent gadofosveset trisodium--an interrater reliability study

Purpose

In this study, image quality of leg veins and vena cava inferior was scored by independent raters using the new intravascular magnetic resonance imaging (MRI) contrast agent gadofosveset trisodium using fat-suppressed 3D gradient echo Volume Interpolated Breath-hold Examination.

Material and methods

The leg venous system without clinical signs of deep venous thrombosis (DVT) and sonography-ruled out DVT were imaged using a fat-suppressed 3D gradient echo Volume Interpolated Breath-hold Examination (VIBE FS). Image interpretation was done independently by two experienced radiologists (raters) using a 5-point scoring system.

Results

High diagnostic image quality with an overall mean visibility score of 4.8 ± 0.1 was acquired in patients enrolled in the study using gadofosveset trisodium-enhanced MRI for the venous system of the leg. There were no cases with moderate, poor or nondiagnostic image quality. Additionally, an excellent interrater reliability was observed.

Conclusions

This study shows the feasibility of acquiring high resolution images with excellent image quality of the venous system of the leg using gadofosveset trisodium.     

Diagnostic performance of USPIO-enhanced MRI for lymph-node metastases in different body regions: A meta-analysis

Objectives

USPIO (ultrasmall superparamagnetic iron oxide contrast agent) MRI was a promising imaging modality in the detection of lymph-node metastases. And this meta-analysis is performed to compare the diagnostic accuracy of USPIO-enhanced MRI with non-enhanced MRI, USPIO-enhanced MRI in various body regions, and postcontrast alone for diagnosis of lymph-node metastases.

Methods

A comprehensive and systematic search was conducted in PubMed and EMBASE databases. After a systematic review of the studies, sensitivity, specificity, the Q* value and other measures of accuracy of USPIO-enhanced MRI in the diagnosis of lymph-node metastases were summarized. The overall test performance was based on summary receiver operating characteristic curves.

Results

Summary of ROC curve analysis for per-lymph-node data shows a pooled sensitivity of 0.90 (95% confidential interval [CI]: 0.88-0.91) and overall specificity of 0.96 (95% CI: 0.95-0.97) for USPIO-enhanced MRI, the Q* value for USPIO-enhanced MRI is 0.9195, diagnostic odds ratio (DOR) is 162.28 (95% CI: 91.82-286.81). Non-enhanced MRI had less overall sensitivity 0.39 (95% CI: 0.34-0.43) and specificity 0.90 (95% CI: 0.89-0.91), respectively, the Q* value for USPIO-enhanced MRI was 0.6321, DOR is 5.81 (95% CI: 3.64-9.82). Postcontrast MRI alone had sensitivity 0.85 (95% CI: 0.81-0.88) and specificity 0.93 (95% CI: 0.91-0.95), respectively, the Q* value for USPIO-enhanced MRI was 0.8976, DOR is 76.92 (95% CI: 34.21-172.93). There was significant heterogeneity for studies reporting enhanced MRI and non-enhanced MRI.

Conclusions

This meta-analysis has shown that USPIO-enhanced MRI offers higher diagnostic performance than conventional MRI, and is sensitive and specific for the detection of lymph-node metastases. Postcontrast images alone can equate diagnostic performance pre- and postcontrast MRI has achieved for lymph-node characterization. And the role of USPIO-enhanced MRI in clinical practice still needs to be investigated in future studies.     

Prospective comparison of image quality and diagnostic accuracy of 0.5 molar gadobenate dimeglumine and 1.0 molar gadobutrol in contrast-enhanced run-off magnetic resonance angiography of the lower extremities

Purpose

To compare image quality and diagnostic accuracy of 0.5 molar gadobenate dimeglumine and 1.0 molar gadobutrol in contrast‐enhanced (CE) magnetic resonance angiography (MRA) of the lower extremities interindividually.

Materials and Methods

The study was approved by our Institutional Review Board. Written informed consent was obtained from all patients before enrollment in the study. We prospectively included 74 patients (21 women, 53 men; mean age ± SD: 67.9 ± 11.0 years) with suspected peripheral occlusive vascular disease. All patients underwent a contrast‐enhanced MRA of both lower extremities with either 0.1 mL/kg body weight gadobutrol or gadobenate dimeglumine. Image quality, stenosis grade, and artifacts were assessed by two blinded, independent investigators. Signal intensity (SI), signal‐to‐noise ratio (SNR), and contrast‐to‐noise ratio (CNR) were measured by a third investigator. Contrast agent groups were compared to each other using a two‐sided Student's t‐test.

Results

The results did not show significant differences for SI, SNR, or CNR. Both investigators were in significant accordance (P < 0.05) with regard to stenosis detection.

Conclusion

We conclude that application of standard clinical doses (0.1 mL/kg body weight) of both contrast agents provides similar diagnostic results and gadolinium dose could be reduced by the application of a single dose of gadobenate dimeglumine for CE run‐off MRA. J. Magn. Reson. Imaging 2010;32:1166–1171. © 2010 Wiley‐Liss, Inc.     

Evaluation of the effects of intravascular MR contrast media (gadolinium dendrimer) on 3D time of flight magnetic resonance angiography of the body

The aims of this preliminary study were to establish the efficacy and minimum effective dose of TG₅(FdDO3A)₅₂ gadolinium dendrimer for contrast-enhanced, three-dimensional (3D) time of flight (TOF) magnetic resonance angiography (MRA) of the body. In a dose ranging study in eight rabbits (Group A), each of two animals received 0.03; 0.02; 0.01; or 0.005 mmol/kg of the agent for 3D-TOF MRA of the pelvic circulation in the axial and coronal planes. An additional nine animals (Group B) received a dose of 0.02 mmol/kg for 3D-TOF MRA of the mediastinum, abdomen or of the lower limbs. Quantitative and qualitative analyses of the images from Group A demonstrated a dose-related reduction in saturation effects and improved visualization of vascular structures, with maximal augmentation of the contrast-to-noise ratio (CNR) at 0.03 mmol/kg. The dose of 0.02 mmol/kg was found to be the minimal effective dose at the three vascular regions.